BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatment options for cancer, this morning announced that its Bria-IMT will be featured in a poster session during this year’s San Antonio Breast Cancer Symposium (“SABCS”), to be held December 4-8, 2018, in San Antonio, Texas. The poster highlights data on Bria-IMT’s use as a monotherapy demonstrating positive proof-of-concept, as well as an initial safety and tolerability assessment for its use in combination with pembrolizumab [KEYTRUDA – manufactured by Merck & Co., Inc. (NYSE: MRK)] for advanced breast cancer. Thomas Jefferson University assistant professor of medical oncology and main principal investigator (PI) of the study Saveri Bhattacharya, DO, will present the poster. Copies of the abstract and the poster will be available on the company’s website following the presentation.
“Despite years of research and improved treatments for breast cancer, according to the latest figures by American Cancer Society, over 40,000 people are expected to die of breast cancer in the United States this year, presenting a large unmet medical need,” BriaCell President and CEO Dr. Bill Williams stated in the news release. “Several challenges need to be addressed, including improving efficacy, safety, and containing the cost of care. At BriaCell, we have been working to resolve all these issues. Bria-IMT has demonstrated positive proof-of-concept in advanced breast cancer, and we will delve into these data in San Antonio. We have firm grounds to believe the anti-tumor effects of Bria-IMT can be greatly improved by combination with KEYTRUDA. We are excited with the early clinical findings of this novel treatment approach and look forward to presenting our data.”
To view the full press release, visit http://ibn.fm/yZQUI
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment